Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Scala

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Human Molecular Genetics|May 27, 2005
CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndromeFrancesca Mari, Sara Azimonti, Ilaria Bertani, et al.
International Journal of Cancer|February 14, 2013
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyEmanuele Valtorta, Sandra Misale, Andrea Sartore-Bianchi, et al.
Nature|June 23, 2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerSandra Misale, Rona Yaeger, Sebastijan Hobor, et al.
Cancer Discovery|June 5, 2013
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerAlberto Bardelli, Simona Corso, Andrea Bertotti, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Human Molecular Genetics|May 27, 2005
CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndromeFrancesca Mari, Sara Azimonti, Ilaria Bertani, et al.
International Journal of Cancer|February 14, 2013
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyEmanuele Valtorta, Sandra Misale, Andrea Sartore-Bianchi, et al.
Nature|June 23, 2012
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerSandra Misale, Rona Yaeger, Sebastijan Hobor, et al.
Cancer Discovery|June 5, 2013
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerAlberto Bardelli, Simona Corso, Andrea Bertotti, et al.
Pageof 2